Gilead Sciences Total Liabilities

The latest total liabilities for GILD is $33B as of March 2026. That compares with $37B in the prior-year period — down 12.3% year over year. Investors often review this figure alongside Gilead Sciences's historical trend and sector peers before judging valuation or financial health.

Over the past year, GILD's total liabilities moved from $37B to $33B — a 12.3% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Gilead Sciences's operating scale or balance-sheet position.

A total liabilities figure of $33B for GILD is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting GILD's total liabilities ($33B), review year-over-year change from $37B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Gilead Sciences's total liabilities against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.